Sự thoát khỏi kháng thể trung hoà của các biến thể protein gai SARS-CoV-2

Al‐Riyami, 2020, Clinical use of convalescent plasma in the covid‐19 pandemic: a transfusion‐focussed gap analysis with recommendations for future research priorities, Vox Sanguinis, 158, 10.1111/vox.12973

Andino, 2015, Viral quasispecies, Virology, 479-480, 46, 10.1016/j.virol.2015.03.022

Barnes, 2020, Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies, Cell, 182, 828, 10.1016/j.cell.2020.06.025

Baum, 2020, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science, 369, 0831, 10.1126/science.abd0831

Bloch, 2020, Deployment of convalescent plasma for the prevention and treatment of COVID-19, Journal of Clinical Investigation, 130, 2757, 10.1172/JCI138745

Brouwer, 2020, Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability, Science, 369, 643, 10.1126/science.abc5902

Burnett, 1986, Immunoglobulins in the lung, Thorax, 41, 337, 10.1136/thx.41.5.337

Cao, 2020, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells, Cell, 182, 73, 10.1016/j.cell.2020.05.025

Chen, 2020, Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor, Cellular & Molecular Immunology, 17, 647, 10.1038/s41423-020-0426-7

Chi, 2020, A potent neutralizing human antibody reveals the N-terminal domain of the spike protein of SARS-CoV-2 as a site of vulnerability, bioRxiv, 10.1101/2020.05.08.083964

Combe, 2014, Variation in RNA Virus Mutation Rates across Host Cells, PLOS Pathogens, 10, 10.1371/journal.ppat.1003855

Dearlove, 2020, A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants, PNAS, 117, 23652, 10.1073/pnas.2008281117

Denison, 2011, Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity, RNA Biology, 8, 270, 10.4161/rna.8.2.15013

Dolan, 2018, Mapping the Evolutionary Potential of RNA Viruses, Cell Host & Microbe, 23, 435, 10.1016/j.chom.2018.03.012

Duffy, 2008, Rates of evolutionary change in viruses: patterns and determinants, Nature Reviews Genetics, 9, 267, 10.1038/nrg2323

Elbe, 2017, Data, disease and diplomacy: GISAID's innovative contribution to global health, Global Challenges, 1, 33, 10.1002/gch2.1018

Gaebler, 2019, Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir, Journal of Experimental Medicine, 216, 2253, 10.1084/jem.20190896

Greaney, 2020, Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition, bioRxiv, 10.1101/2020.09.10.292078

Hansen, 2020, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science, 369, 1010, 10.1126/science.abd0827

Hsieh, 2020, Structure-based design of prefusion-stabilized SARS-CoV-2 spikes, Science, 369, 1501, 10.1126/science.abd0826

Ju, 2020, Human neutralizing antibodies elicited by SARS-CoV-2 infection, Nature, 584, 115, 10.1038/s41586-020-2380-z

Kellam, 2020, The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection, Journal of General Virology, 101, 791, 10.1099/jgv.0.001439

Kk, 2020, COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing, Clinical Infectious Diseases, 25, 10.1093/cid/ciaa1275

Kk, 2020, Serum antibody profile of a patient with COVID-19 reinfection, Clinical Infectious Diseases, 23, 10.1093/cid/ciaa1368

Korber, 2020, Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus, Cell, 182, 812, 10.1016/j.cell.2020.06.043

Kreer, 2020, Longitudinal isolation of potent Near-Germline SARS-CoV-2-Neutralizing antibodies from COVID-19 patients, Cell, 182, 1663, 10.1016/j.cell.2020.08.046

Larson, 2020, A case of early Re-infection with SARS-CoV-2, Clinical Infectious Diseases, 19, 10.1093/cid/ciaa1436

Liu, 2020, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike, Nature, 584, 450, 10.1038/s41586-020-2571-7

Luchsinger, 2020, Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID19 patients, Journal of Clinical Microbiology, 11, 10.1128/JCM.02005-20

Moya, 2000, The evolution of RNA viruses: A population genetics view, PNAS, 97, 6967, 10.1073/pnas.97.13.6967

Plotkin, 2010, Correlates of protection induced by vaccination, Clinical and Vaccine Immunology, 17, 1055, 10.1128/CVI.00131-10

Rambaut, 2020, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology, Nature Microbiology, 5, 1403, 10.1038/s41564-020-0770-5

Rausch, 2020, Low genetic diversity may be an achilles heel of SARS-CoV-2, PNAS, 117, 24614, 10.1073/pnas.2017726117

Robbiani, 2020, Convergent antibody responses to SARS-CoV-2 in convalescent individuals, Nature, 584, 437, 10.1038/s41586-020-2456-9

Rogers, 2020, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model, Science, 369, eabc7520, 10.1126/science.abc7520

Schmidt, 2020, Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses, Journal of Experimental Medicine, 217, 10.1084/jem.20201181

Seydoux, 2020, Analysis of a SARS-CoV-2-Infected individual reveals development of potent neutralizing antibodies with limited somatic mutation, Immunity, 53, 98, 10.1016/j.immuni.2020.06.001

Shi, 2020, A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2, Nature, 584, 120, 10.1038/s41586-020-2381-y

Singer, 2020, CoV-GLUE: a web application for tracking SARS-CoV-2 genomic variation, Preprints, 10.20944/preprints202006.0225.v1

Steinhauer, 1989, High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus, Journal of Virology, 63, 2063, 10.1128/JVI.63.5.2063-2071.1989

Steinhauer, 1986, Direct method for quantitation of extreme polymerase error frequencies at selected single base sites in viral RNA, Journal of Virology, 57, 219, 10.1128/JVI.57.1.219-228.1986

van Dorp, 2020, Emergence of genomic diversity and recurrent mutations in SARS-CoV-2, Infection, Genetics and Evolution, 83, 10.1016/j.meegid.2020.104351

Van Elslande, 2020, Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain, Clinical Infectious Diseases, 5, 10.1093/cid/ciaa1330

Wang, 2020, Enhanced SARS-CoV-2 neutralization by secretory IgA in vitro, bioRxiv, 10.1101/2020.09.09.288555

Wec, 2020, Broad neutralization of SARS-related viruses by human monoclonal antibodies, Science, 369, 731, 10.1126/science.abc7424

Wölfel, 2020, Virological assessment of hospitalized patients with COVID-2019, Nature, 581, 465, 10.1038/s41586-020-2196-x

Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C. 2020a. A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. medRxiv. https://science.sciencemag.org/content/368/6496/1274.

Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S. 2020b. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2.

Yan, 2020, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science, 367, 1444, 10.1126/science.abb2762

Yuan, 2020, Structural basis of a shared antibody response to SARS-CoV-2, Science, 369, 1119, 10.1126/science.abd2321

Zost, 2020, Potently neutralizing and protective human antibodies against SARS-CoV-2, Nature, 584, 443, 10.1038/s41586-020-2548-6